Episodes

  • What Neurologists Should Know About End-of-Life Care Discussions

    What Neurologists Should Know About End-of-Life Care Discussions
    Jul 19 2024
    Dan Morhaim, MD, board-certified emergency medicine and internal medicine physician, and former 24-year Maryland State Legislator, highlights the importance of discussing end-of-life care issues with dementia patients and best practices for physicians to follow when broaching this topic.
    Show more Show less
    21 mins
  • Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders

    Insights into the Role of Tau in Alzheimer Disease and Neurodegenerative Disorders
    Jul 15 2024
    Virginia Man-Yee Lee, PhD, who serves as the John H. Ware 3rd Endowed Professor in Alzheimer's Research at the University of Pennsylvania Perelman School of Medicine, the Director of the Center for Neurodegenerative Disease Research, and Co-Director of the Marian S. Ware Center for Alzheimer's Drug Discovery, presents an overview of tau biomarker testing and research.
    Show more Show less
    22 mins
  • Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

    Strategies to Limit ARIA Associated with Alzheimer Disease Treatment
    Jul 15 2024
    Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab.
    Show more Show less
    9 mins
  • Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab

    Real-World Implications Beyond Cognition in Treating Alzheimer Disease Patients with Donanemab
    Jul 15 2024
    Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss recent data analyzing the real-world implications of donanemab treatment for people with Alzheimer disease.
    Show more Show less
    9 mins
  • Emerging Therapeutic Targets for Alzheimer Disease

    Emerging Therapeutic Targets for Alzheimer Disease
    Jul 15 2024
    Howard Fillit, MD, geriatrician, neuroscientist, and Chief Science Officer and Co-Founder of the Alzheimer's Drug Discovery Foundation, discusses the importance of research into new therapeutic targets to develop next-generation treatments for Alzheimer disease, including small molecule compounds.
    Show more Show less
    14 mins
  • Progress in Diagnosis and Management of Neuropsychiatric Symptoms in People Living with Dementia

    Progress in Diagnosis and Management of Neuropsychiatric Symptoms in People Living with Dementia
    Jul 7 2024
    George Grossberg, MD, Samuel W. Fordyce Professor and Director of Geriatric Psychiatry, Saint Louis University School of Medicine, provides an overview of recent progress in the evaluation, diagnosis, and treatment of neuropsychiatric symptoms in people living with dementia, including nonpharmacologic and pharmacologic interventions.
    Show more Show less
    13 mins
  • How Healthcare Providers Can Partner with Caregivers of People Living with Dementia

    How Healthcare Providers Can Partner with Caregivers of People Living with Dementia
    Jul 7 2024
    Dementia care expert, gerontologist, and author, Laura Wayman provides insights into what caregivers for people living with dementia need from healthcare providers and how clinicians can best partner with caregivers.
    Show more Show less
    18 mins